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57 ABSTRACT 
Heterologous polypeptides are produced in the milk of 
transgenic non-human mammals by the expression of a 
Stably integrated DNA sequence containing the long whey 
acidic protein promoter operably linked to a DNA sequence 
encoding a heterologous polypeptide and a signal Sequence. 
The transgenic non-human mammals of the present inven 
tion are produced by introducing this DNA sequence Such 
that the DNA sequence is stably integrated into the DNA of 
germ line cells of the mature mammal and inherited in 
normal Mendelian fashion. A representative heterologous 
polypeptide is protein C. 
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EXPRESSION OF A HETEROLOGOUS 
POLYPEPTIDE IN MAMMARY TISSUE OF 
TRANSGENIC NON-HUMAN MAMMALS 
USING ALONG WHEY ACIDIC PROTEIN 
PROMOTER 
This application is a continuation-in-part of U.S. Ser. No. 
07/638,995, filed Jan. 11, 1992, which is herein incorporated 
by reference. 
The present invention relates to the production of natural 
and modified forms of the human coagulation factor protein 
C. In particular, the invention relates to a transgenic animal 
containing, stably incorporated in its genomic DNA, an 
exogenous gene which is expressed specifically in mammary 
tissue, Such that protein C is Secreted into milk produced by 
the animal. In particular, the invention relates to the pro 
duction of natural and modified forms of protein C in the 
milk of a transgenic non-human mammal using a DNA 
molecule that comprises a long whey acidic protein pro 
moter fragment and genomic DNA encoding human protein 
C. The long whey acidic protein promoter fragment also can 
be used to express high levels of other genes in mammary 
cells of transgenic non-human mammals. 
BACKGROUND OF THE INVENTION 
Protein C is an important component of the coagulation 
System that has strong anticoagulant activity. In its active 
form it is a Serine protease that proteolytically inactivates 
Factors V, and VIII. 
Human protein C (hPC) is a 62 kD, disulfide-linked 
heterodimer consisting of a 25 kD light chain and a 41 kD 
heavy chain which circulates as an inactive Zymogen in 
plasma. At the endothelial cell Surface it is activated to 
activated protein C (APC) by limited thrombin proteolysis in 
the presence of thrombomodulin, cleavage of an Arg-Leu 
bond in the amino terminal portion of the heavy cain releases 
a 12 amino acid peptide. See generally Gardiner & Griffin in 
PROGRESS IN HEMATOLOGY, Vol. XIII at page 265-278 
(Brown, Grune and Stratton, Inc. 1983). 
Several regions of the molecule have important implica 
tions for function as an anticoagulant in the regulation of 
hemostasis. The amino terminal portion of the light chain 
contains the nine Y-carboxyglutamic acid (Gla) residues 
required for calcium-dependent membrane binding and 
functional activation. Another post-translational modifica 
tion is B-hydroxylation of aspartic acid reside 71, possibly 
required for calcium-dependent membrane binding which is 
independent of the binding activity of the Gla regions. 
There are a variety of clinical Situations for which protein 
C may prove beneficial. It may serve as replacement therapy 
in homozygous deficient infants Suffering from purpura 
fulminans neonatalis. Other conditions include patients with 
a previous history of warfarin-induced skin necrosis who 
must have additional warfarin therapy, heparin-induced 
thrombocytopenia, Septic shock for prevention of intravas 
cular coagulation and organ damage, and for fibrinolytic 
therapy, as protein C can protect t?A from plasma inhibitor 
proteins. Table 1 represents one estimate of the number of 
individual cases of Several clinical Syndromes which might 
be treated by purified protein C. Because there has not been 
Sufficient material available from plasma for clinical trials 
until recently, these data are necessarily based on an incom 
plete assessment of the therapeutic potential for protein C. 
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TABLE 1. 
PARTIAL ESTIMATE OF U.S. CLINICAL REOUIREMENTS 
FOR PROTEIN CAND ACTIVATED PROTEIN C 
Estimated 
Dose (mg) # Treatments Total U.S. 
Indication Per Treatment Per Year Req. (Kg) 
Septic Shock 5-50 120,000 0.6-6.0 
Thrombolytic Therapy * 10-100 800,000 8-8O 
Hip Replacement 10-100 200,000 2-20 
Homozygous Deficient 3 100 x 365* O.10 
Heterozygous Deficient 50 1,000 O.OS 
Total 10.8-106.2 
* 100 individuals in U.S. x 365 treatment/year 
**Refers to the use of APC, following thrombolytic therapy, to prevent the 
reformation of blood clots. 
The gene for human protein C has been cloned and 
Sequenced, as has bovine protein C gene. See Forster et al., 
Proc. Nat'l Acad. Sci. USA 82: 4673 (1985); U.S. Pat. No. 
4,775,624. It is synthesized as an inactive precursor that 
undergoes Several proteolytic events during the processes of 
Secretion and activation. First, a signal Sequence as pro 
teolytically removed upon Secretion. A Second proteolytic 
event removes the dipeptide lyS156 arg157, producing the 
inactive Zymogen, a two chain disulfide bridged protein, 
consisting of a light chain of 155 amino acids and a heavy 
chain of 262 amino acids. The Zymogen is activated by a 
final proteolytic event that removes residues 158-169, yield 
ing active protein C, a Serine protease with potent antico 
agulant activity. Beckmann et al., Nucleic Acids Res. 13: 
5233 (1985). 
In addition to proteolytic processing, human protein C 
undergoes Several post-translation modifications. Perhaps 
most Salient among these modifications is the 
Y-carboxylation of the first nine glutamic acid residues in 
protein C, by a vitamin K dependent enzyme. DiScipio & 
Davie, Biochemistry 18: 899 (1979). Gamma-carboxylation 
is required for anticoagulant activity, and is associated with 
Caf'-dependent membrane binding. The anticoagulant 
activity of protein C varies directly with the extent of 
Y-carboxylation, and the highest levels of activity are 
achieved only when Y-carboxylation of the sixth and seventh 
glutamic acid residues is effected. Zhang & Castellino, 
Biochemistry 29: 10829 (1990). 
Protein C is also post-translationally modified by 
B-hydroxylation of aspartic acid 71. Drakenberg et al., Proc. 
Nat'l Acad. Sci. USA 80: 1802 (1983). Beta-hydroxylation 
may be important to protein C activity. Although its function 
is not known it has been Suggested that it may be involved in Y-carboxyglutamic acid independent Cabinding, and it 
may be required for full anti-coagulant activity. 
Human protein C is also glycosylated. Kisiel, J. Clin. 
Invest. 64: 761 (1979). It contains four potential N-linked 
glycosylation sites, located at ASn97, ASn248, ASn313 and 
ASn329. The first three signals match the consensus ASn 
X-Ser/Thr glycosylation Sequences, and are actively glyco 
Sylated. There is an atypical glycosylation signal at ASn329, 
Asn-X-Cys-Ser. The ASn329 signal is glycosylated in 
bovine protein C, but it is not yet known if ASn329 is 
glycosylated in human protein C. Miletich et al., J. Biol. 
Chem. 265: 11397 (1990). The pattern and extent of glyco 
Sylation can alter the physiological activity of protein C. 
Until recently, human protein C for experimental and 
therapeutic use was obtained exclusively from human 
plasma. Unfortunately, the quantity of protein that can be 
obtained from human Serum is limited. Furthermore, prod 
5,831,141 
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ucts derived from human serum pose difficulties of 
reliability, purity and Safety. 
The expression of therapeutic proteins by recombinant 
DNA technology is an attractive alternative to plasma pro 
duction of protein C, in that it eliminates the risk of potential 
contamination with blood-borne viruses and theoretically 
provides an unlimited Supply of product. But the complexity 
of the post-translational modifications, as discussed above, 
has rendered problematic the production of commercially 
uSeable amounts of Suitably active protein C by expression 
in a heterologous host. 
In fact, it has not been possible to produce Vitamin 
K-dependent proteins like protein C at Sufficiently high 
levels in an active form, despite efforts to do So using a 
variety of expression Systems. See Grinnell et al. in Volume 
11 of ADVANCES IN APPLIED BIOTECHNOLOGY 
SERIES, Chapter 3 (Gulf Publishing Co.). In particular, any 
prospect for expressing protein C in mammary glands of a 
transgenic animal and Secreting the protein into milk, See, 
e.g., U.S. Pat. No. 4,873,316 (1989), is clouded by the fact 
that protein C is normally synthesized in the liver. Even 
HepG2 cell lines derived from human liver produce aberrant 
forms of protein C. Marlar & Fair (1985). 
In this regard, it has been observed that a mouse mam 
mary epithelial cell line (C-127) transfected with a bovine 
papilloma virus (BPV) vector bearing the cDNA for human 
protein C expressed protein C that was only 30-40% active. 
Further analysis revealed that the protein C contained dimin 
ished levels of Y-carboxyglutamic acid and little, if any, 
B-hydroxyaspartic acid. Suttie et al., Thrombosis Res. 44: 
129 (1986). These experiments indicate that mouse mam 
mary epithelial cells cannot perform all of the post 
translational modifications necessary for obtaining Suitably 
active protein C, which in turn casts doubt on the likelihood 
of obtaining Such protein C from the milk of a transgenic 
mammal. 
SUMMARY OF THE INVENTION 
It is therefore an object of the present invention to provide 
a transgenic animal which produces in its milk recombinant 
protein C that comprises a Significantly higher percentage of 
active protein than has been achieved heretofore. 
It is another object of the present invention to provide a 
proceSS for producing protein C in commercially useable 
amounts, by means of a transgenic mammal. 
In accomplishing the foregoing objects, there has been 
provided, in accordance with one aspect of the present 
invention, a transgenic mammal containing an exogenous 
DNA sequence Stably integrated in its genome, wherein the 
exogenous DNA sequence comprises a promoter operably 
linked to a DNA sequence encoding a polypeptide having 
protein C activity and a signal peptide, wherein the promoter 
is specifically active in mammary cells, particularly mam 
mary epithelial cells, and the Signal peptide is effective in 
directing the secretion of the protein C into the milk of the 
transgenic mammal. 
In a preferred embodiment, the promoter is a whey acidic 
protein promoter. In a highly preferred embodiment the 
promoter comprises substantially the 5' 4.2 kb Sau3A-Kpn1 
promoter fragment of the mouse whey acidic protein gene, 
or a variant thereof. 
In another aspect in a preferred embodiment the DNA 
Sequence encoding a polypeptide having human protein C 
activity comprises portions of the non-coding regions of the 
human protein C gene. In a particularly preferred embodi 
ment of this type the DNA sequence gene comprises Sub 
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Stantially the human protein C gene from 21 basepairs 
upstream of the protein C start codon to the Nhe site in the 
3' end of the protein C gene, or a variant thereof is among 
the most highly preferred. 
In a particularly preferred embodiment, the exogenous 
DNA sequence comprises a DNA sequence consisting essen 
tially of the 5' 4.2 kb Sau3A-Kpn1 promoter fragment of the 
mouse whey acidic protein promoter ligated directly or by a 
linker to a fragment of the human protein C gene beginning 
21 basepairs upstream of the protein C Start codon and 
ending at the Nhe site in the 3' end of the protein C gene. 
In accordance with another aspect of the present 
invention, there has been provided a process for the pro 
duction of protein C, comprising the steps of (A) providing 
a transgenic mammal characterized by an exogenous DNA 
Sequence Stably integrated in its genome, wherein the exog 
enous DNA sequence comprises a promoter operably linked 
to a DNA sequence encoding a polypeptide having protein 
C activity and a signal peptide, the promoter being Specifi 
cally active in mammary cells and the Signal peptide being 
effective in directing the Secretion of the protein C into the 
milk of the transgenic mammal; (B) producing milk from the 
transgenic mammal, (C) collecting the milk, and (D) isolat 
ing the polypeptide from the milk. 
In a highly preferred embodiment of this aspect of the 
invention, the promoter comprises substantially the 5' 4.2 kb 
Sau3A-Kpn1 promoter fragment of the mouse whey acidic 
protein gene, or a variant thereof. 
Additionally, in a preferred embodiment the DNA 
Sequence encoding a polypeptide having human protein C 
activity comprises portions of the non-coding regions of the 
human protein C gene. In a particularly preferred embodi 
ment of this type the DNA sequence gene comprises Sub 
Stantially the human protein C gene from 21 basepairs 
upstream of the protein C start codon to the Nhe site in the 
3' end of the protein C gene, or a variant thereof is among 
the most highly preferred. 
In addition, is certain a particularly preferred 
embodiment, the exogenous DNA sequence comprises a 
DNA sequence consisting essentially of the 5' 4.2 kb Sau3A 
Kpn1 promoter fragment of the mouse whey acidic protein 
promoter ligated directly or by a linker to a fragment of the 
human protein C gene beginning 21 basepairs upstream of 
the protein C start codon and ending at the Nhe site in the 
3' end of the protein C gene. 
In accordance with Still another aspect of the present 
invention, a process has been provided for producing trans 
genic animals, comprising the steps of (A) providing a 
mixture containing a genetic construct; (B) Subjecting the 
mixture to anion-exchange high performance liquid chro 
matography to obtain purified genetic construct; and there 
after (C) microinjecting an aqueous buffer Solution contain 
ing the purified genetic construct into an animal embryo. In 
a preferred embodiment, step (B) comprises applying the 
mixture to an anion-exchange high performance liquid chro 
matography column, eluting the genetic construct from the 
column, and then Subjecting the genetic construct to a 
Second anion-exchange high performance liquid chromatog 
raphy. 
In a preferred embodiment of this aspect of the invention, 
the double-stranded DNA is selected from the group con 
Sisting of a double-Stranded DNA comprising Substantially 
the 5' 4.2 kb Sau3A-Kpn1 promoter fragment of the mouse 
whey acidic protein promoter, a double-Stranded DNA com 
prising Substantially a fragment of the human protein c gene 
beginning 21 basepairs upstream of the protein C Start codon 
5,831,141 
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and ending at the Nhe site in the 3' end of the protein C 
gene, and a double-Stranded DNA comprising a DNA 
Sequence consisting essentially of the 5' 4.2 kb Sau3A-Kpn1 
promoter fragment of the mouse whey acidic protein pro 
moter ligated directly or by a linker to a fragment of the 
human protein C gene beginning 21 basepairs upstream of 
the protein C start codon and ending at the Nhe site in the 
3' end of the protein C gene. 
In accordance with yet another aspect of the invention, 
there has been provided a process for the production of a 
polypeptide in the milk of a transgenic non-human mammal, 
comprising the Steps of providing a non-human transgenic 
mammal characterized by an exogenous DNA sequence 
Stably integrated in its genome, wherein Said exogenous 
DNA sequence comprises substantially the 5' 4.2 kb Sau3A 
- Kipn1 promoter of the mouse whey acidic protein gene, or 
a variant thereof, operably linked to a DNA sequence 
encoding Said polypeptide and a signal peptide, Said pro 
moter being Specifically active in mammary cells and Said 
Signal peptide being effective in directing the Secretion of 
Said polypeptide into the milk of Said transgenic mammal; 
producing milk from Said transgenic mammal; collecting 
Said milk, and isolating Said polypeptide from Said milk. In 
a particularly preferred embodiment of this aspect of the 
invention, the exogenous DNA sequence comprises the 5' 
4.2 kb Sau3A - Kipn1 promoter fragment of the mouse whey 
acidic protein promoter. 
The accordance with yet another aspect of the invention 
there has been provided a transgenic non-human mammal 
containing an exogenous DNA sequence Stably integrated in 
its genome, wherein the exogenous DNA sequence com 
prises substantially the 4.2 kb Sau3A-Kpn1 whey acidic 
protein promoter fragment, or a variant thereof, operably 
linked to a DNA encoding a polypeptide whereby the protein 
is expressed specifically in mammary cells of the transgenic 
mammal and the protein comprises a signal peptide, the 
peptide being effective in directing the Secretion of the 
protein into the milk of Said mammal. In a particularly 
preferred embodiment of this aspect of the invention, the 
exogenous DNA sequence comprises the 5' 4.2 kb Sau3A 
Kpn1 promoter fragment of the mouse whey acidic protein 
promoter. 
In certain preferred embodiments of various aspects of the 
invention, the transgenic mammal is mouse, rabbit, pig, 
sheep or goat. In Some most highly preferred embodiments 
the animal is pig or sheep. 
Other objects, features and advantages of the present 
invention will become apparent from the following detailed 
description. It should be understood, however, that the 
detailed description and the Specific examples, while indi 
cating preferred embodiments of the invention, are given by 
way of illustration only, Since various changes and modifi 
cations within the Spirit and Scope of the invention will 
become apparent to those skilled in the art from this detailed 
description. 
BRIEF DESCRIPTION OF THE FIGURES 
FIG. 1 is a schematic diagram representing WAPpCI, a 
construct which contains cDNA encoding human protein C 
inserted into an intact murine whey acidic protein (WAP) 
gene at the unique Kpn1 site. 
FIG. 2 is a Schematic representation of polymerase chain 
reaction (PCR) primer pairs useful to detect WAP-protein C 
DNAS in transgenic animals. 
FIG. 3 is a graph that shows the results of an enzyme 
linked immunosorbent assay (ELISA) of human protein C in 
milk obtained from a transgenic mouse. 
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FIG. 4 is a graph that shows the results of an APTT assay 
to determine human protein C anti-coagulant activity in 
whey obtained from a transgenic mouse. 
FIG. 5 is a graph that shows the results of Ca"-dependent 
and Cat"-independent light chain capture ELISAS which 
demonstrate that the Y-carboxyglutamic acid in human pro 
tein C in whey from transgenic mouse Y52 is similar to that 
in protein C derived from human Serum. 
FIG. 6 is a Schematic diagram representing a highly 
preferred murine WAP-human protein C construct. In this 
construct, a 4.2 kb 5’ murine whey acidic protein promoter 
fragment is linked to a 9.4 kb genomic fragment encoding 
human protein C which includes the 400 bp extending from 
the end of exon VIII to the Nhe site in the 3' end of the 
human protein C gene. The sequence of the WAP-hPC 
junction (SEQ ID NO: 1) is shown above the schematic 
diagram. 
FIG. 7 is a photograph showing the results of western 
analyses of human protein C production in the milk of 
transgenic animals. Panel A shows the proteins in whey 
Samples resolved by PAGE under reducing conditions and 
visualized by silver staining. Panel B shows the proteins 
detected by anti-human protein C antibodies in a western 
blot of an identical gel, Visualized by chemiluminescence. 
Lanes were loaded with approximately 5 lug of protein. 
Lanes 1 through 6 contained, respectively, Samples from 
transgenic mice 5.4, 6.4, 4.2.10, 5.2.12, 7.2.2 and 7.5.4. 
Lane 7 contained a Sample from a non-transgenic mouse. 
Lane 8 contained purified human protein C. “SC'-single 
chain hPC, “HC'-heavy chain forms of hPC, “LC"-light 
chain hPC. 
FIG. 8 shows the amidolytic activity in samples of whey 
from transgenic mice. Panel A ShowS amidolytic activity of 
whey proteins resolved by PAGE under native conditions. 
Panel B shows the proteins detected by anti-hPC antibodies 
in a Western blot of an identical gel, Visualized using 
4-chloro-1-naphthol. Lanes were loaded with approximately 
50 ug of protein. Lane 1 contained purified human protein C. 
Lane 2 contained a Sample form a non-transgenic mouse. 
Lanes 3 through 8 contained, respectively, Samples from 
transgenic mice 7.5.4, 7.2.2, 5.2.12, 4.2.10, 6.4 and 5.4. 
DETAILED DESCRIPTION OF THE 
INVENTION 
Notwithstanding past failures to express recombinant 
protein C with Suitably high activity in several different 
expression Systems, including transformed mammary cells, 
it has been discovered that recombinant protein C charac 
terized by a high percentage of active protein can be 
obtained in the milk of transgenic animals that incorporate 
DNAS according to the present invention. Transgenic ani 
mals of the present invention are produced by introducing 
into developing embryos DNA that encodes protein C, Such 
that the DNA is stably incorporated in the DNA of germ line 
cells of the mature animal and inherited in normal, mende 
lian fashion. 
In accordance with the invention, DNAS can be intro 
duced into embryos by a variety of means to produce 
transgenic animals. For instance, totipotent or pluripotent 
Stem cells can be transformed by microinjection, calcium 
phosphate mediated precipitation, liposome fusion, retrovi 
ral infection or by other means. The transformed cells can 
then be introduced into embryos and incorporated therein to 
form transgenic animals. In a preferred method, developing 
embryos can be infected with retroviral vectors and trans 
genic animals can be formed from the infected embryos. In 
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the most preferred method, however, the DNAS of the 
invention are injected into embryos, preferably at the Single 
cell Stage, which are allowed to develop into mature trans 
genic animals. 
Suitable protein C-encoding DNA used for producing 
transgenic animals in this fashion can be obtained using 
human liver tissue as a Source for cloning the hPC gene. The 
DNA coding for protein C can be fused, in proper reading 
frame, with appropriate regulatory signals, as described in 
greater detail below, to produce a genetic construct which is 
then amplified, for example, by propagation in a bacterial 
vector, according to conventional practice. 
The amplified construct is thereafter excised from the 
vector and purified for use in microinjection. The purifica 
tion is preferably accomplished by means of high perfor 
mance liquid chromatography (HPLC), which rids the con 
Struct of contamination from the bacterial vector and from 
polysaccharides typically present when other techniques, 
Such as conventional agarose electroelution, are used. The 
preferred HPLC method entails sorbing the construct onto 
an anion-exchange HPLC Support and Selectively eluting the 
construct from the Support, preferably with an aqueous 
Sodium chloride Solution, thereby to eliminate contamina 
tion from the vector. (Elution may be effected by other 
means, Such as a pH gradient.) Alternatively but less 
preferably, the excised construct can be purified by ultra 
centrifugation through an aqueous Sucrose gradient. 
Since it is preferable that the construct have the minimum 
amount of impurities, more than one cycle of HPLC or other 
purification is advantageous. In particular, the use of HPLC 
purified DNA for microinjection, as described above, allows 
for remarkably high transformation frequencies, on the order 
of 20% or more in both mice and pigs. 
All lactating animals, that is, all mammals, are Suitable for 
use according to the present invention. Preferred mammals 
include mice, rats, rabbits, pigs, sheep, goats and cows. 
More particularly, mice, pigs, sheep and cows are preferred. 
Most preferred at present are mice, pigs and sheep. 
DNA constructs useful in the present invention provide a 
DNA sequence encoding protein C operably linked to all the 
cis-acting Signals necessary for mammary tissue specific 
expression of protein C, post-translational modification of 
protein C, Secretion of protein C into milk, and full biologi 
cal activity of protein C. 
DNAS useful in the invention include genomic or comple 
mentary DNAS that encode naturally occurring protein C. In 
a preferred embodiment DNAS encoding human protein C 
are employed, including CDNA and genomic DNAS. DNAS 
encoding protein C from other Species may also be used, 
Such as the protein C encoded by rats, pigs, sheep, cows and 
chimpanzees. 
In a particularly preferred embodiment, human genomic 
DNAS encoding protein C are employed. Among the most 
highly preferred human genomic DNAS is the fragment of 
the human protein C gene beginning 21 basepairs upstream 
of the protein C start codon and ending at the Nhe site in the 
3' end of the protein C gene. This fragment, approximately 
9.4 kb long, contains regulatory elements that engender high 
expression of human protein C in the milk of non-human 
transgenic mammals. Some of these regulatory elements are 
the AUG start codon, donor and acceptor Splice Signals, the 
Secretion peptide, and the translation termination, transcrip 
tion termination and polyadenylation Signals. 
It will be appreciated that there may be additional regu 
latory elements in the fragment that aid the production of 
transgenic non-human mammals that express high levels of 
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protein C in their milk. Some of these signals may be 
transcription or translation control Signals, or those associ 
ated with transport out of the cell. Other Signals may play a 
role in efficient chromosomal integration or Stability of the 
integrated DNA. Various regions of the fragment may con 
tain Such Signals, Such as the region between the end of exon 
VIII and the Nhe site in the 3' end of the protein C gene. 
It will be readily appreciated that deletional and other 
mutational techniques may be employed to elucidate further 
all the Signals in this fragment that confer high levels of 
protein C expression in the milk of transgenic animals. 
It will also be appreciated that the 9.4 kb protein C 
fragment described above can be modified using recombi 
nant DNA techniques in an almost infinite number ways. 3' 
or 5" portions of the protein C gene can be added, or a few 
bases at either end may be removed. Introns can be removed 
or added. Portions of one or more introns can be deleted. 
Additional DNA can be inserted into them. The sequences of 
the introns can be altered. Exons can be modified in accor 
dance with the discussion of modified protein C molecules 
set forth below. Most such modified forms of the preferred 
genomic protein C fragment will not be significantly 
changed in their ability in transgenic animals to engender the 
production of milk-born protein C. Thus, these substantially 
Similar fragments will be equivalent in the invention to the 
particularly disclosed 9.4 kb fragment of human protein C 
that begins 21 basepairs upstream of the protein C Start 
codon and ends at the Nhe site in the 3' end of the protein 
C gene. 
Modified protein C Sequences also can be employed in the 
present invention. Useful modifications in this context 
include but are not limited to those that alter the post 
translational processing of protein C, that alter the size of 
protein C, that fuse protein C or portions thereof to portions 
of another protein, or that alter the active Site of protein C. 
Preferred modifications include those that provide an acti 
vated protein C and those that provide for activation of 
protein C in the absence of thrombomodulin. In a preferred 
embodiment, modified forms of human protein C are 
employed. 
Such modifications can be introduced into protein C by 
techniques well known to the art, Such as the Synthesis of 
modified genes by ligation of Overlapping oligonucleotide, 
and by introducing mutations directly into cloned genes, as 
by oligonucleotide mediated mutagenesis, inter alia. 
The cis-acting regulatory regions useful in the invention 
include the promoter used to drive expression of the protein 
C gene. Promoters useful in the invention are active in 
mammary tissue. Particularly useful are promoters that are 
Specifically active in mammary tissue, i.e., are more active 
in mammary tissue than in other tissues under physiological 
conditions where milk is synthesized. Most preferred are 
promoters that are both Specific to and efficient in mammary 
tissue. By “efficient' it is meant that the promoters are Strong 
promoters in mammary tissue that can Support the Synthesis 
of large amounts of protein for Secretion into milk. 
Among Such promoters, the casein, lactalbumin and lac 
toglobulin promoters are preferred, including, but not lim 
ited to the Cl-, 3- and Y-casein promoters and the 
a-lactalbumin and Y-lactoglobulin promoters. Preferred 
among the promoters are those from rodent (murine and rat), 
pigs and sheep, especially the rat B-casein promoter and the 
sheep f-lactoglobulin promoter. The most preferred promot 
ers are those that regulate a whey acidic protein (WAP) gene, 
and the most preferred WAP promoter is the murine WAP 
promoter. 
5,831,141 
A most highly preferred promoter is the 4.2 kb Sau3A 
Kpn1 promoter fragment of the mouse whey acidic protein 
promoter. It has been found that this fragment is highly 
efficacious in directing the production of high levels of a 
protein in the milk of a transgenic animal. In the case of 
human protein C this mouse whey acidic protein promoter 
fragment has engendered the production of active protein C 
in the milk of transgenic animals in concentrations above 4 
mg/ml (by polyclonal ELISA). 
It will be readily appreciated, as for the 9.4 kb protein C 
genomic DNA discussed above, the 4.2 kb Sau3A-Kpn1 
whey acidic protein promoter fragment can be modified by 
recombinant DNA techniques readily available to those of 
ordinary skill in the art. Thus, the fragment can be shortened, 
keeping in mind that the 2.4 kb 5’ WAP promoter fragment 
gives rise to very much lower yields. It can be lengthened to 
include more of the whey acid protein promoter region or 
other portions of the whey acid protein gene. Portions can be 
removed, and DNA can be inserted into the fragment. 
Internal bases can be altered. In the majority of cases these 
alternatives will not affect the ability of this promoter 
fragment to induce very high levels of expression. Frag 
ments modified in this way, giving the expected high yields 
of protein in transgenic milk, are Substantially similar vari 
ants of the 4.2 kb 5’ promoter fragment. They also are useful 
in the present invention and are functionally equivalent in 
this respect to the 4.2 kb Sau3A-Kpn1 whey acidic protein 
promoter fragment itself. 
Also important to the invention are the Signal Sequences 
that direct Secretion of protein into the milk of the transgenic 
animal. In this regard, both endogenous and heterologous 
Signal Sequences are useful in the invention. Generally, the 
Signal peptides of proteins normally Secreted into milk are 
useful in the invention. The Signal Sequences of proteins that 
occur in high concentration in milk are particularly 
preferred, Such as the Signal peptides of the caseins, lactal 
bumins and lactoglobulins, including, but not limited to the 
Signal peptides of the Cl-, 3- and Y-caseins and a-lactalbumin 
and B-lactoglobulin. More particularly, the Signal Sequence 
of whey acidic protein is preferred, most particularly the 
Signal Sequence of the murine whey acidic protein. 
Also particularly preferred are the Signal peptides of 
Secreted coagulation factors. Especially preferred in this 
regard are the Signal peptides of protein C, and t-PA. Most 
especially preferred is the Secretion signal of human protein 
C. 
Among the Sequences that regulate transcription that are 
useful in the invention, in addition to the promoter 
Sequences discussed above, are enhancers, Splice Signals, 
transcription termination Signals and polyadenylation sites, 
among others. Particularly useful regulatory Sequences 
increase the efficiency of mammary cell Specific expression 
of protein C in transgenic animals. 
Especially useful in this regard are the other transcription 
regulatory Sequences of genes expressed at high levels in 
mammary cells, Such as the Cl-, 3- and Y-casein genes and the 
C.-lactalbumin and B-lactoglobulin genes mentioned above. 
Preferred Sources for regulatory Sequences in this regard are 
rodents (mice and rats), pigs and sheep. 
Exemplary of preferred regulatory Sequences are those 
asSociated with the rat B-casein gene and the sheep 
B-lactoglobulin gene, respectively. The regulatory 
Sequences most preferred for use in the present invention are 
those associated with whey acidic protein genes. Particularly 
preferred in this context are regulatory Sequences of the 
murine whey acidic protein. 
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Among the Sequences that regulate translation, in addition 
to the Signal Sequences discussed above, are ribosome 
binding Sites and Sequences that augment the Stability the 
protein C mRNA. Especially useful are the translation 
regulatory Sequences of genes expressed at high levels in 
mammary cells. For instance, the regulatory Sequences of 
the Cl-, 3- and Y-casein genes and the a-lactalbumin and 
B-lactoglobulin genes are preferred, especially those from 
rodents (mice and rats), pigs and sheep. Even more particu 
larly preferred are the regulatory Sequences of rat B-casein 
and the sheep B-lactoglobulin genes. 
The most preferred translational regulatory Sequences of 
the invention are those of the whey acidic protein and the 
protein C genes. And the most particularly preferred regu 
latory Sequences are those of the murine whey acidic protein 
and human protein C, including human genomic protein C 
and human protein C CDNA constructs, and including 
human protein C cl)NA constructs that contain intron 
Sequences. Among these, the most highly preferred are the 
regulatory Sequences of the human protein C gene in the 
region beginning 21 basepairs upstream of the protein C 
start codon and ending at the Nhe site in the 3' end of the 
protein C gene, and the regulatory Sequences of the mouse 
whey acidic protein promoter in the 5' 4.2 kb Sau3A-Kpn1 
promoter fragment of the mouse whey acidic protein 
promoter, most particularly when they are used together. 
Especially useful in the present invention are Sequences 
that advantageously modulate post-translational modifica 
tions of protein C, Such that the protein C produced in the 
transgenic animals of the invention is active. In particular, 
the genomic Sequences of the human protein C gene are 
preferred. 
Thus, in accordance with the present invention a DNA 
Sequence that encodes protein C is operably linked to 
cis-acting regulatory Sequences which allow for efficient 
expression of protein C in milk. The resulting chimeric DNA 
is introduced into a mammalian embryo, where it integrates 
into the embryonic genome and becomes part of the heri 
table genetic endowment of all the cells, including the germ 
line cells, of the adult which develops from the embryo. The 
protein C which is expressed in the mammary tissue and 
Secreted into the milk of a transgenic mammal obtained in 
this manner displays a Surprisingly high percentage of active 
protein, as measured by enzymatic and coagulation 
inhibition assays which are conventionally employed to 
detect protein C activity, Such as ELISAS, chromogenic 
activity assays and coagulation inhibition assayS. Levels of 
active protein on the order of 80% to 90% or more are 
characteristic of the protein C expressed in accordance with 
the present invention. 
Obtaining milk from a transgenic animal within the 
present invention is accomplished by conventional means. 
McBurney et al., J. Lab. Clin. Med. 64: 485 (1964). The 
protein C contained in Such milk can be purified by known 
means without unduly affecting activity. One Suitable 
approach to purification in this regard is immunoaffinity 
chromatography. Alternatively, the expressed protein C can 
be isolated from the milk by other conventional means, for 
instance, by the method of Kisiel, J. Clin. Invest. 64: 761 (1979). In any event, it is preferred that protein C produced 
in milk pursuant to the present invention should be isolated 
as Soon as possible after the milk is obtained from the 
transgenic mammal, thereby to mitigate any deleterious 
effect(s) on the stability of the protein. 
The present invention is further described by reference to 
the following, illustrative examples. 
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EXAMPLE 1. 
DNAS Useful for Expressing Protein C in 
Transgenic Animals 
The entire murine WAP gene including 2.5 kb of 5' 
untranslated Sequence and 3' untranslated regions was 
cloned by standard methods. See Campbell et al., Nucleic 
Acids Res. 12:8685 (1984). The human placental cDNA for 
human protein C was obtained from C. Shoemacker. Human 
genomic DNAS encoding protein C were cloned by Standard 
methods from a human placental genomic library. The 9.4 kb 
fragment was assembled from two genomic clones and a 
Sali, Mse ended 60 bp synthetic oligonucleotide that was 
added to the 5' end of the gene. 
Standard recombinant DNA techniques were employed to 
generate the vectors and expression constructs of the pre 
ferred embodiments, and for other manipulations of DNA, 
as set forth below. See Sambrook et al., MOLECULAR 
CLONING, A LABORATORY MANUAL, Vol. 1-3 (Cold 
Spring Harbor Press 1989). 
(1) WAPpC1 
A DNA construct called WAPpC1 was made, consisting 
of the entire murine WAP gene containing one copy of 
human protein C cDNA inserted at the unique KpnI site, 24 
base pairs 3' of the transcriptional start site of the WAP gene 
(FIG. 1). This WAP protein C construct was ligated into a 
blueScribe vector (Stratagene) to facilitate further manipu 
lation. 
(2) WAPpC2 
WAPpC2 is similar to WAPpC1, comprising the entire 
murine WAP gene and human protein C clNA but differs 
from WAPpC1 in lacking artefactual 5' flanking sequences 
present in WAPpC1 as a result of cloning procedures used to 
make that construct. Specifically, 33 bp 5' to the protein C 
ATG and 118 “A’s” at the 3' end of the protein C cDNA were 
removed by PCR, and new Kipni sites were added at the 5' 
and 3' ends. 
EXAMPLE 2 
Preparation of DNAS for Microinjection 
DNA for microinjection was prepared according to the 
procedures described below for DNA from WAPpC1. 
The 9 kb WAPpC1 fragment was removed from the vector 
with the restriction enzyme EcoRI. After digestion with 
EcoRI the solution containing the WAPpC1 DNA was 
brought to 10 mM magnesium, 20 mM EDTA and 0.1% SDS 
and then extracted with phenol/chloroform. DNA was pre 
cipitated from the aqueous layer with 2.5 volumes of ethanol 
in the presence of 0.3 M sodium acetate at -20° C. over 
night. After centrifugation, the pellet was washed with 70% 
ethanol, dried, and resuspended in Sterile distilled water. 
DNA for microinjection was purified by HPLC. The 
digested DNA was precipitated with isopropanol and then 
dissolved in TE buffer at 0.3 ug/ml. Fragments were purified 
by HPLC using a Waters GEN FAX PAC HPLC column. 
The column was run isocratically using a buffer consisting 
of 25 mM Tris-HCl (pH 7.5), 1 mM sodium EDTA, and 
0.63M NaCl. This is the minimum NaCl concentration that 
will elute the large construct fragment and results in the best 
resolution from the Smaller vector fragment which elutes just prior to the construct fragment. About 15 lug of digested 
DNA was loaded on the column at a time. The construct 
fragment Samples from all of the chromatographic runs were 
then pooled, reprecipitated, and run through the column a 
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Second time. Results reported below, for both pigs and mice, 
were generated using HPLC-purified DNA. 
DNA concentrations were determined by agarose gel 
electrophoresis by Staining with ethidium bromide and com 
paring the fluorescent intensity of an aliquot of the DNA 
with the intensity of Standards. Samples were then adjusted 
to 10 ug/ml and stored at -20°C., prior to microinjection. 
EXAMPLE 3 
Transgenic Animals 
(1) Mice 
Transgenic mice were produced essentially as described 
by Hogan et al., MANIPULATING THE MOUSE 
EMBRYO (Cold Spring Harbor Press 1986). The proce 
dures employed are outlined below. 
Glass needles for micro-injection were prepared using a 
micropipet puller and microforge. Injections were per 
formed using a Nikon microscope having Hoffman Modu 
lation Contrast optics, with Narashigi micromanipulators 
and a pico-injector driven by N (Narashigi). 
Fertilized mouse embryos were Surgically removed from 
the oviducts of Superovulated female CD-1 mice and placed 
into M2 medium. Cumulus cells were removed from the 
embryos with hyaluronidase at 300 tug/ml. The embryos 
were then rinsed in new M2 medium, and transferred into 
M16 medium for storage at 37 C. prior to injection. 
After injecting the DNA solution into the male 
pronucleus, embryos were implanted into avertin 
anesthetized CD-1 recipient females made pseudo-pregnant 
by mating with vasectomized males. Embryos were allowed 
to come to term and the newborn mice were analyzed for the 
presence of the transgene as described below. 
(2) Pigs 
Embryos were recovered from the oviduct. They were 
placed into a 1.5 ml microfuge tube containing approxi 
mately 0.5 ml embryo transfer media (phosphate buffered 
saline +10% fetal calf serum, Gibco BRL). These were then 
centrifuged for 12 minutes at 16,000xg RCF (13.450 RPM) 
in a microcentrifuge (Allied Instruments, model 235C). 
Embryos were removed from the microfuge tube with a 
drawn and polished Pasteur pipette and placed into a 35 mm 
petri dish for examination. If the cytoplasm was still opaque 
with lipid such that pronuclei are not visible, the embryos 
were centrifuged again for 15 minutes. Embryos to be 
microinjected were placed into a microdrop of media 
(approximately 100 ul) in the center of the lid of a 100 mm 
petri dish. Silicone oil was used to cover the microdrop and 
fill the lid to prevent media from evaporating. The petri dish 
lid containing the embryos was set onto an inverted micro 
Scope (Carl Zeiss) equipped with both a heated Stage and 
Hoffman Modulation Contrast optics (200x final 
magnification). A finely drawn (Kopf Vertical Pipette Puller, 
model 720) and polished (Narishige microforge, model 
MF-35) micropipette was used to stabilize the embryos 
while about 1-2 picoliters of HPLC-purified DNA solution 
containing approximately 200-500 copies of DNA construct 
was delivered into the male pronucleus with another finely 
drawn micropipette. Embryos Surviving the microinjection 
process as judged by morphological observation were 
loaded into a polypropylene tube (2 mm ID) for transfer into 
the recipient pig. 
(3) Other Animals 
Methods for microinjection of other animal Species are 
similar to the methods set forth above. 
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EXAMPLE 4 
Assessment via PCR of WAP/hPC Constructs in 
Transgenic Animals 
(1) Preparation of DNA form Transgenic Animals 
DNA can be prepared from tissue of a transgenic animal 
of any species by the method exemplified below for mice. 
A 5 mm piece of mouse tail was removed from young, 
potentially transgenic mice at weaning (3 weeks of age), 
minced, and treated with proteinase K and SDS at 37 C. 
overnight. The mixture was then incubated with DNase-free 
RNase at 37 C. for 1-2 hours. DNA was precipitated from 
the mixture with sodium acetate and ethanol at -20° C. 
overnight, collected by centrifugation, washed in 70% etha 
nol and dried. The dried DNA pellet was used directly for 
PCR. In some cases the mixture was extracted extensively 
with phenol/chloroform prior to ethanol precipitation. 
Essentially the same technique was used to prepare DNA 
from pigs, and the same or similar techniques can be used to 
prepare DNA from other animals. 
(2) Oligonucleotide Probes used in the PCR Assay 
Oligonucleotide pairs were used to prime polymerase 
chain reactions that detected the presence of WAP-protein C 
constructs in the transgenic animals. These pairs and their 
extension products are shown schematically in FIG. 2 Oli 
gonucleotide pairs that bridge the region from the WAP 
sequences 5' of the KpnI site and the endogenous WAP 
Sequences which naturally lie 3' of the Kipni Site also 
provided positive controls in mice. 
(3) PCR Reaction Conditions and Product Analysis 
PCR reactions were performed using an annealing tem 
perature of 58 C., a denaturation temperature of 94 C., and 
an extension temperature of 72 C., using 100 ng of oligo 
primers and 50 ng of (genomic) template DNA per reaction, 
and cycling through the temperatures 40 times using an 
automatic temperature cycler (M.J. Research). 
PCR reactions were analyzed by running 20% of the 
reaction products on agarose gels and identifying fragment 
sizes by comparison with marker DNA fragments. 
(4) Results of PCR Analysis of Transgenic Animals 
PCR analysis of potentially transgenic mice and pigs 
which developed from embryos microinjected with 
WAPpC1 and WAPpC2 constructs are summarized in Table 
2. The results show that WAPpC constructs frequently 
integrated into the embryonic genomes of both mice and 
pigs. Furthermore, mendelian transmission was observed in 
5 of the 16 mice which were tested. 
TABLE 2 
Whey Acid Protein-Protein C Construct Integration Rates 
Animal # Tested # Positive Integration Rate 
Mice 105 3O 29% 
Pigs 23 5 22% 
Mendelian Transmission in Transgenic Mice 
5/16 Tested = 31% 
EXAMPLE 5 
Preparation of Milk and Whey from Transgenic 
Animals 
(A) Mice: Lactating mice were milked an average of 3 
times per week. The mice were first Separated from their 
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young for approximately 5 hours. They were then anesthe 
tized with 0.4 ml avertin at 2.5% (I.M.), and 0.2 ml oxytocin 
was then administered at 2.5 IU/ml (I.P) to permit release of 
the milk. A milking device consisting of a vacuum pump (2.5 
psi) and Syringe with an eppendorf tip was used to direct 
milk into an eppendorf tube. During collection, milk was 
placed on ice until all Samples were obtained. 
To prepare whey, milk was diluted 1:1 with TS buffer 
(0.03M Tris pH 7.4; 0.06 NaCl) and centrifuged in a 
TLA-100 rotor in a Beckman TL-100 table top ultracentri 
fuge at 51,000 rpm (89,000xg) for 30 minutes at 4°C. After 
centrifugation the tubes were put on ice, and the whey was 
collected with an 18 gauge needle, leaving the casein pellet 
and upper cream layer in the tube. To remove Solids or cream 
that co-transferred during the initial recovery, the whey 
obtained from the first centrifugation was Subjected to a 
second spin at 12,000 rpm for 30 minutes at 4 C. in a 
TMA-4 rotor in a Tomy MTX-150 centrifuge. Following the 
Second Spin the tubes were place on ice and the whey was 
recovered as before. 
EXAMPLE 6 
Determination by ELISA of Protein C Produced by 
Transgenic Mammals 
An ELISA was used to measure the amount of protein C 
protein produced by transgenic animals in their milk or 
whey. Two monoclonal antibodies, 7D7B10 and 12A8, and 
a polyclonal antiserum were used in the ELISAS, and a 
variety of other protein C specific antibodies could be 
employed. The 7D7B10 monoclonal is specific for the NH 
terminus of the light chain of protein C. 12A8 is specific for 
the reactive site on the heavy chain of protein C. 
Microtiter plate wells were coated overnight at 4 C. with 
3 ug/ml of monoclonal antibody in 50 ul of 0.1M sodium 
bicarbonate buffer, pH 8.3. The wells were washed once 
with TET buffer (0.01M Tris pH 7.5; 0.01M EDTA; 0.02% 
tween-20, pH 7.45) and then blocked with 1% BSA in PBS 
using 400 ul per well for 1 hour at 37 C. Plates were again 
washed with TET buffer (5x) followed by addition of 100 ul 
of Sample whey or normal whey Spiked with human protein 
C from plasma, to generate a Standard curve. After washing 
5x with TET buffer, horse radish peroxidase (HRP)- 
conjugated to rabbit anti-hPC was diluted 1:1000 in 0.1% 
BSA/TET and 100 ul was added per well and incubated for 
2 hours at room temperature, with Shaking at 100 rpm. After 
again washing 5 times with TET buffer, 100 ul of orthophe 
nyldiamine (OPD), from a stock solution made by dissolv 
ing one tablet of OPD in 20 ml of 0.1M citrate-phosphate 
buffer (pH 5.0), were added to each well. After 10 minutes 
at room temperature the reaction was Stopped with 1N 
sulfuric acid. The extent of the reaction was determined by 
measuring product absorption at 490 nm. 
The result of an ELISA analysis of the milk from one 
transgenic mouse (Mouse No. 5) is shown in FIG. 3. 
Standard curves were obtained for a monoclonal antibody, 
12AB, and a rabbit polyclonal antibody, tittered against 
human protein C which was obtained by immunoaffinity 
chromatography over immobilized 7D7B10 antibody. The 
milk Sample, taken from transgenic Mouse No. 5, contained 
approximately 200 ng/ml protein C. 
To assure proper protein C Structure as judged by immu 
nocapture by two different monoclonal antibodies, as well as 
by a polyclonal mixture of antibodies, the Samples for 
Several different transgenic mice were Screened by ELISAS. 
Table 2A shows essentially equivalent antigen levels, as 
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judged by three different immunocaptures and detection by 
ELISA. The majority of mice produced by microinjection of 
WAPpC1 produced antigen levels in the 1-to-4-lig/ml range. 
TABLE 2A 
hPC ANTIGEN ELISA (NG/ML) 
MOUSE MONOCLONAL MONOCLONAL POLYCLONAL 
ID-DAY LC-CAPTURE HC-CAPTURE CAPTURE 
Y52-15 182O 353O 41OO 
Y57-15 930 1150 288O 
The concentration of human protein C in whey obtained 
from transgenic mice, as well as milk, was also determined 
in this manner, with equivalent results. 
Similar assays were routinely carried out to assay protein 
C in milk obtained from transgenic animals. Results 
obtained using the 7D7B10 antibody in light-chain capture 
ELISAS are compiled in Table 3, which Summarizes the 
concentration of protein C in milk obtained from transgenic 
mice during the first four lactation periods. Dashes indicate 
that no test was done. All of the animals provided significant 
levels of protein C in their milk. Preliminary results also 
indicate that the Second lactation period is Sometimes Supe 
rior to the other periods tested. 
TABLE 3 
hPC ELISA SCREENING (LIGHT CHAIN CAPTURE) 
Day of Lactation 
MOUSE ID 5-6 8-9 11-12 13-15 
Y68-L2 1.05 
Y51-L2 1.08 O.56 
YS1-L3 2.8O 1.30 1.79 
Y52-L1 0.55 O.65 
Y52-L2 1.52 0.95 
Y57-L1 0.52 1.35 
Y57-L2 1.47 O.98 
RO3-L2 1.90 2.88 3.01 
R12-L1 O60 
R12-L2 2.98 2.48 240 
Human protein C in the milk obtained from other species 
can be measured by the same methods. Thus, protein C from 
human plasma Spiked into pig milk was accurately detected 
via the above-described ELISA. 
EXAMPLE 7 
Assay for Protein C Amidolytic Activity using the 
Chromogenic Substrate S-2366 
(1) Microtiter Well Assay 
The enzymatic activity of protein C in the milk of 
transgenic animals was measured directly using a chromoge 
nic assay essentially as described by Odegaard et al., Hae 
mostasis 17: 109 (1989). In this assay microtiter plate wells 
were coated with the 7D7B10 monoclonal antibody (50 
ug/ml) in 50 ul of 0.1M bicarbonate buffer, pH 8.6 at 4 C. 
overnight. Plates were then rinsed with TET buffer (0.1M 
Tris; 0.03M EDTA; 0.05% tween-20) and blocked with 400 
til/well 1% BSA in PBS and incubated at room temperature 
for 1 to 1.5 hours. After rinsing 3 times with TET buffer, 50 
ul of whey sample and 50 ul of 0.1M Tris pH 7.5, 0.03M 
EDTA was added per well and incubated at room tempera 
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ture for 2 hours. Plates were washed 3 times in TET buffer. 
The captured human protein C was activated by adding 120 
All of Protac", a commercial reagent containing a Snake 
venom enzyme (12 ml distilled water per vial), 30 ul TSP 
buffer and 0.1% BSA, pH 7.5, per well. After incubation for 
6-10 minutes at room temperature, 120 ul S-2366 (Kabi 
substrate) at 25 mg/10.8 ml Tris pH 7.8 was added to each 
well and the plates were incubated for 2-8 hours at room 
temperature, or several days at 4 C. The amount of protein 
C activity in each Sample was determined by measuring 
formation of the reaction product by absorption at 405 mm. 
Results obtained using milk and whey from a transgenic 
mouse and the pooled milk and whey of Several transgenic 
mice appear in Table 4, which shows the amount and the 
specific activity of protein C in the samples. Note that the 
Samples were obtained either during the first lactation 
period, L1, or were obtained from a Second and third 
lactation, L2 and L3. The specific activity of the human 
protein C obtained from transgenic mice determined in these 
assays, 205 units (U) per mg, is similar to that of human 
protein C of similar purity obtained from natural Sources. (A 
“unit' is defined by pooling blood from many individuals 
and determining activity in 1 ml of the pooled blood.) 
TABLE 4 
Protac TM-Specific Amidolytic Activity 
Upon S-2366 
U/ml pig Ag/ml U/mg 
Reconstituted Whey O.O7 O34 2O6 
YS2-L1 Pool*: 
YS2-L1 Milk Pool O.23 1.12 
Transgenic Whey Pool** 1.12 0.55 205 
Transgenic Milk Pool** O.43 2.10 
*Pooled milk from days 5-15. 
**L2 and L3 from mice Y51, Y52, Y57, RO3, R12. 
(2) Amidolytic activity assay on nitrocellulose 
Whey proteins were resolved by electrophoresis through 
polyacrylamide gels under non-reducing conditions in the 
presence of SDS. Following electrophoresis proteins were 
transferred out of the gel and immobilized on a nitrocellu 
lose membrane by electroblotting. SDS was removed from 
the membrane by thorough washing in 0.05M Tris-Cl, 
0.175M NaCl, .25% Triton X-100, pH 8.0, and the mem 
brane was then equilibrated in 0.25M Tris-Cl pH 8.0. 
Following equilibration the membrane was incubated in 
Protac C, 0.25 U/ml in distilled water. A 1% agarose 
indicator gel in 25 mM Tris-Cl pH 8 containing 1 mM 
chromogenic Substrate S-2366 was then placed onto the gel, 
and the filter and gel overlay were incubated under moist 
conditions for 30–90 minutes at 37 C. Colored bands 
generated by protein C activity on the filter were Visualized 
under U.V. light, and photographed. 
FIG. 8 shows the results obtained by this assay for milk 
produced by transgenic mice that were Stably transformed 
with a double stranded DNA comprising the 5' 4.2 kb WAP 
promoter ligated via a linker to the 9.4 kb human genomic 
protein C fragment. All of these transgenic mice produced 
amidolytically active protein C in their milk, giving rise in 
the blots to a strong band and a weak band of amidolytic 
activity (FIG. 8, panel A). Notably, bands of the same 
migration were detected in each whey Sample when a similar 
blot was probed with an anti-protein C antibody (FIG. 8, 
panel B). 
EXAMPLE 8 
Determination of Protein C Produced in Transgenic 
Mammals by Activated Partial Thromboplastin 
Clotting Time ASSay 
The activity of protein C was also measured in a clotting 
time assay, the activated partial thromboplastin clotting time 
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assay (APTT). In this assay, each well of a plastic Coag-a- 
mate tray received 90 ul of PC-deficient plasma plus 10 ul 
of an APC standard or unknown, diluted with Tris/saline/ 
BSA. The tray was then placed on an automated analyzer 
(APTT mode, 240 second activation). The run was started, 
which automatically performed the addition of 100 ul of 
APTT reagent and 100 ul of 0.025M CaCl. Data obtained 
using a Standard APC preparation was fitted to the equation 
y-ax+b where y=clotting time and x=APC, which was then 
used to determine the amount of APC in a sample. 
The result of an APTT assay of whey pooled from 
transgenic mice is shown in FIG. 4. The Standard curves in 
the figure correlate the activity determined by the APTT 
assay with the amount of active human protein C in mouse 
milk or mouse whey. The activity in the APTT assay of the 
whey Sample obtained from the transgenic mouse corre 
sponded to a concentration of approximately 0.57 ug/ml, 
interpolated from the Standard curve for human protein C in 
whey. An ELISA (not shown) of the same whey sample 
detected approximately 0.60 ug/ml of human protein C, as 
protein. Thus, within the normal range of error of these 
assays, human protein C produced in transgenic mice is as 
active as the control human protein C. 
EXAMPLE 9 
Mapping of Calcium Dependent Conformer by 
Metal-Dependent Immunoaffinity 
Standard ELISAS were run in normal mouse milk whey 
with varying concentrations of hPC or hPC without Gla 
regions in the presence of 25 mM EDTA. After capture by 
7D7B10, an assay replicating that effected with 25 mM 
EDTA was treated with several washes of 25 mM CaCl, and 
then was followed by the ELISA detection protocol 
described previously. While de-Gla protein remained bound 
to the capture antibody in the presence of CaCl2, the PC 
Standard did not remain bound in the presence of added 
CaCl2. It was observed that whey from the transgenic mouse 
Y57 behaved in a similar manner to the y-carboxylated 
native PC, Suggesting that it is also y-carboxylated like the 
native molecule. 
EXAMPLE 10 
Purification of Human Protein C from the Milk of 
Transgenic Animals 
(1) Preparation of Whey Samples 
Milk from several WAPpC1 transgenic mouse lines was 
pooled, chilled on ice, diluted 6-fold with 50 mM Tris-HCl, 
0.15M NaCl pH 7.2 (TBS) (1 ml milk per 5 ml TBS), and 
centrifuged at 125,000xg for 30 minutes at 4 C. Following 
centrifugation, the whey was collected and pooled using a 
pasteur pipet and pooled, being careful not to disturb the 
fatty Overlayer or the casein pellet. Samples were removed 
from the pool for later assay and then both the Samples and 
the pooled whey were frozen and stored at -90° C. Human 
protein C in Samples was determined by ELISA, as 
described above. 
Individual whey pools were thawed at 2 C.C, combined, 
and the amount of human protein C (hPC) in the combined 
pool was determined by ELISA using the 7D7B10 mono 
clonal antibody (Mab). The combined pool contained 
approximately 30 lighPC, determined by this assay, which 
was within 20% of the total determined by adding determi 
nations of the individual pools. 
The combined pool, approximately 150 ml, was dialyzed 
(14,000 MW cutoff) against 25 mM EDTA-TBS diluted 
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5-fold with pure water. The dialyzed whey was concentrated 
5-fold by lyophilization and Subsequent reconstitution with 
nanopure water, to yield a final buffer concentration equiva 
lent to 25 mM EDTA in TBS, and a 5-fold increase in protein 
concentration. The concentrated whey contained 930 mg 
protein, as estimated by optical absorption at 280 nm, at 16 
mg/ml. 
(2) Immunoaffinity Chromatography 
The resin immunosorbent (AffiprepTM) used to purify 
human protein C in the whey of transgenic mice contained 
3.3 mg 7D7B10 Mab/ml of Affiprep resin. The 7d7B10 
Affiprep resin was assessed by mock immunopurification 
using 30 tug of plasma derived hPC doped into control 
(nontransgenic) mouse whey. Approximately the same rela 
tive amount of total protein was loaded onto the column (660 
mg on a 10 mL Affiprep) and otherwise processed as 
described below. 
Freshly concentrated whey (16 mg/ml, 930 mg total 
protein, as determined by optical absorption at 280 nm) was 
batch-loaded onto 13 ml of 7D7B10 Affiprep containing 3.3 
mg 7D7B10 Mab/ml resin for 4 hours at 2 C., without 
addition of carrier protein. The column was fresh and the 
high total (background) protein loading was thought to be 
enough to condition the column. The resin was then loaded 
into a 1 cm diameter column and washed with 25 mM 
EDTA-TBS until baseline optical density (O.D.) was 
detected at 280 nm (3 column volumes to obtain <0.0005 
O.D.) 
The column was then eluted with 25 mM CaCl in TBS 
pH 7.2, followed by 100 mM CaCl in TBS, followed by 4M 
NaCl, followed by 2M Na thiocyanate at 0.5 ml/min. The 
column was re-equilibrated with 5 column volumes of 25 
mM EDTA-TBS, 0.02% sodium azide. 
All peak pools were dialyzed in a 100-fold dilution (by 
nanopure water) of 50 mM imidazole, 0.1M NaCl buffer 
using a 14,000 MW cutoff dialysis tubing, then lyophilized, 
then reconstituted to 50 mM imidazole, 0.1. NaCl buffer 
Strength using nanopure water resulting in a 100-fold con 
centration of protein. 
Samples of these eluate pool concentrates were prepared 
as per the method of Laemmli (1970), applied to a 15 well, 
9 cmx2 cm, 4% stacking gel above a 7.5 cm, 7.5% resolving 
(30%: 2.7% bis) sodium dodecylsulphate polyacrylamide 
gel and electrophoresed (SDS-PAGE). After electrophoresis, 
the gel was stained with 1.25% Coomassie Blue dye solu 
tion. 
The area of the eluate peaks obtained from immunopuri 
fication of whey from WAPpC1-transgenic mice was found 
to be very Similar to the mock trial using an equivalent 
amount of (plasma derived) hPC-doped whey from control 
mice. Assay of 100-fold concentrated 25 mM CaCl eluate 
product from WAPpC1 transgenics showed 40% yield based 
upon densitometry of SDS-PAGE stained with Coomassie 
Blue (yield not determined for mock purification). The total 
peak areas from mock- and WAPpC1 -whey were approxi 
mately the same for all eluate peaks including the 2M Na 
thiocyanate peak. Approximately 2 tug of hPC antigen 
(ELISA with immunocapture using 7D7B10 Mab) was 
detected in the column fall through which had been com 
bined with EDTA-TBS wash. Approximately 14 lug of hPC 
was detected in the 25 mM Ca" eluate pool, less than 0.1 
ug hPC antigen in the 100 mM Cat" eluate pool, no hPC 
antigen was detected in the 4M NaCl pool, approximately 10 
lug of hPC was detected in the 2M Nathiocynate eluate pool. 
Thus, 87% of the hPC antigen applied to the column was 
accounted for in the total antigen recovered from column 
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effluents. A 47% antigen yield was obtained based upon the 
hPC antigen recovered in the 25 mM Cat" eluate peak. 
The starting whey applied to the column, the 2M sodium 
thiocyanate eluate, the 25 mM Cat eluate product, and a 
reference hPC derived from plasma by the American Red 
Cross (Lot #28300277, supplied by Dr. Carolyn Orthner) 
were analyzed by SDS-PAGE, both reduced and non 
reduced. The 2M sodium thiocynate and 25 mM Caeluate 
pools were concentrated as described above and 4 lug of 
antigen applied to the gel for each lane. The immunopurified 
hPC reference was applied to the gel as 4 ug total protein 
based upon O.D. at 280 nm. Scanning densitometry of this 
reference hPC indicated that the Sample was greater than 
99% pure on nonreduced SDS-PAGE, and 71% pure on 
reduced SDS-PAGE. Subsequent antigen assays performed 
on the hPC reference material indicated the concentration of 
the Sample to be Such that only 2.7 ug of the reference 
sample was applied to the gel. The 25 mM Ca" eluate 
product is greater than 94% pure based upon non-reduced 
SDS-PAGE and 86% pure based upon reduced SDS-PAGE. 
The staining intensity of the 25 mM Cat" eluate lanes is 
consistent with our previous experience for 4 lug antigen 
applications. The bands corresponding to reference hPC 
possessed lighter intensity relative to the 25 mM Ca" 
eluate. A slightly split band at approximately 62,000 relative 
molecular weight (Mr) is seen for both the non-reduced 
reference hPC and the 25 mM Cat" eluate. A doublet at 
about 40,000 Mr and a diffuse single band at 22,000 Mr is 
seen for both the reduced reference hPC and 25 mM Cat" 
eluate. The 22,000 Mr band appearing in the hPC reference 
is seen to be Somewhat more diffuse or heterogeneous than 
the similar band appearing in the 25 mM Ca" eluate from 
the whey of transgenic mice. The Sodium thiocyanate peak 
showed a band in excess of 180,000 Mr in the nonreduced 
sample and multiple bands at 50,000 Mr and 25,000 Mr in 
the reduced Sample. 
The chromatography of the WAPpC1-whey was nearly 
identical to the mock run using plasma-derived hPC doped 
into control whey. The total areas and yields of hPC in the 
25 mM Ca" eluates and areas of 2M sodium thiocyanate 
peaks for both runs were Similar and thus the binding 
characteristics of the 7D7B10 Mab onto transgenic hPC or 
plasma-derived hPC were similar. This is consistent with the 
Similarity found between plasma-derived and transgenic 
hPC Ca"-dependent conformers as judged by ELISA 
assays using the 7D7B10 Mab to immunocapture from 
whey. The primary structure as judged by SDS-PAGE 
appears to be similar, with the amount of C.-form and B-form 
heavy chain being essentially the same for plasma-derived 
and transgenic hPC; the transgenic having 68% C.-form and 
32% ul-form while the plasma-derived material possessed 
69% a-form and 31% B-form. The light chains were also 
similar in size for both reference and transgenic hPC. 
Previous experience with SDS-PAGE using Coomassie Blue 
staining of hPC has shown linearity for both chains over the 
range of 2-5 ugh PC applied to the gel. Thus, much of the 
elements of post-translational, proteolytic processing 
appears to have occurred properly in the mammary tissue. 
The purity of these runs also demonstrates the Satisfactory 
utility of the immunopurification procedure developed for 
the murine system. It is believed that the tight binding of the 
hPC antigen found by ELISA in the 2M thiocyanate peak of 
the whey from transgenic mice (assay not done for mock 
run) is typical of yields found for fresh immunosorbents and 
not due to an aberrant hPC structure. The total background 
protein did not seem to condition the column and thus the 
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interaction is thought to be specific with the 7D7B10 Mab. 
Overall, this two step procedure results in a minimum 
purification factor of 27,000 for the hPC recovered from 
mouse milk. A large-scale purification process could employ 
a citrate or EDTA precipitation coupled with low Speed 
centrifugation in place of the ultracentrifugation Step used 
for mouse milk. 
Both amidolytic and anti-coagulant assays were per 
formed upon immunopurified milk from transgenic mice. 
Within the sensitivity of these assays, the amidolytic and 
anti-coagulant activity was the same as plasma-derived 
immunopurified protein C. For both types of assays, the 
Specific activity was greater than 270 U/mg. 
EXAMPLE 11 
Highly Efficient Expression of Active Protein C in 
Transgenic Mammals using a Long Mouse Whey 
Acid Protein Promoter Fragment and a Human 
Genomic Protein C Fragment 
(A) DNA Constructs 
The 5' 4.2 kb Sau3A-Kpn1 promoter fragment of the 
mouse whey acidic protein promoter was cloned by Standard 
techniques. The 9.4 kb genomic fragment of human protein 
C beginning 21 basepairs upstream of the “A” in the protein 
C start codon and ending at the Nhe site in the 3' end of the 
protein C gene also was cloned by Standard techniques. The 
4.2 kb promoter fragment and the 9.4 kb protein C fragment 
were joined using a SalI linker, as shown in FIG. 6. 
(B) Production of Transgenic Animals 
DNA was prepared and injected into mouse and pig 
embryos as described hereinabove. Animals were tested for 
integration of the DNA by PCR, also as described above. 
Stable integration of the construct was detected in both mice 
and pigs. 
(C) Protein C in the Milk of Transgenic Mice. 
The mice were reared to maturity, crossed and milk was 
obtained from lactating females. 
FIG. 7 depicts SDS-PAGE and western blot analysis of 
whey from Six transgenic mice. AS shown in panel A, 
transgenic mouse whey (lanes 1-6) and normal mouse whey 
(lane 7) gave rise to Substantially the same Silver stain 
pattern of bands after SDS-PAGE. As shown panel B, human 
protein C readily was detected in the transgenic mice whey 
(lanes 1-6), but not in normal mouse whey (7), when the 
Samples were blotted onto nitrocellulose, probed with an 
anti-human protein C antibody, and Visualized by chemilu 
minescence. The pattern of bands detected by the anti 
human protein Cantibody in the transgenic mouse whey was 
very similar to the pattern of bands detected in purified 
human protein C (lane 8). 
As shown in FIG. 8, protein C activity readily could be 
detected in transgenic mouse whey. Panel B in the figure 
shows the pattern of human protein C in mouse whey 
samples resolved by SDS-PAGE under non-reducing con 
ditions. Protein C was visualized by blotting onto 
nitrocellulose, probing the filter with an anti-human protein 
C antibody and detecting antibody binding by a Secondary 
antibody-enzyme conjugate and the chromogenic Substrate 
4-chloro-1-naphthol. Protein C reactive bands were substan 
tially the same in transgenic mice (lanes 3-8) and purified 
human protein C (lane 1), and were absent from normal 
mouse whey (lane 2). 
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Amidolytic activity in the Samples is shown in Panel A. 
An agarose gel Overlay containing chromogenic Substrate 
revealed enzyme activity in whey from each transgenic 
mouse (lanes 3-8) and in purified human protein C (lane 1), 
but not in normal mouse whey (lane 2). 
The amounts of human protein C produced by the trans 
genic mice in their milk also was determined. Table 5 shows 
the amounts of human protein C detected in the milk of Six 
transgenic mice, as determined by 12A8 monoclonal ELISA 
and by sheep anti-human protein C polyclonal ELISA. The 
table also shows protein C amidolytic activity in whey from 
the same samples. The ELISAS and the amidolytic activity 
assay were performed as described hereinabove. 
AS shown in the Table, protein C concentrations in the 
transgenic mice by monoclonal ELISA ranged from approxi 
mately 0.05 mg/ml to approximately 1.69 mg/ml. The con 
centration of protein C in the milk of these mice was at least 
40 fold more than the concentration of protein C observed in 
other transgenic mice, Such as those noted in Table 2A, as Set 
forth hereinabove. 
Concentrations measured by polyclonal ELISA ranged 
from 0.14 to 4 mg/ml, exceeding even more dramatically the 
concentrations attained with the 2.4 kb 5’ WAP promoter, the 
highest of which, as set forth in Table 2A, was 0.0041 
mg/ml. 
In addition, whey samples from the transgenic mice were 
assayed for amidolytic activity and the results were com 
pared with amidolytic activity of protein C in plasma. 
Amidolytic activity in the samples is shown in Table 5, 
expressed as the per cent of protein C activity in plasma. The 
concentration of protein C in the whey Samples was adjusted 
to equal the concentration in the normal plasma control. 
The high concentration of protein C allowed the amidol 
ytic activity to be assayed directly in whey. This contrasted 
Sharply with the necessity to use a capture method to 
concentrate protein C prior to amidolytic activity of whey 
samples from mice transgenic for the 2.4 kb WAP promoter 
fragment. 
The amidolytic activity of protein C in the whey sample 
was also compared with the activity of purified human 
protein C diluted in whey. At comparable concentrations of 
protein C, amidolytic activity in transgenic mouse whey was 
nearly the same as that of human protein C. 
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TABLE 5 
Detection of human protein C in the milk of 
transgenic mice having the 5' 4.2 kb WAP-promoter 
9.4 kb human genomic protein C construct stably 
integrated in their genomes 
PC PC ANTIGEN 
TRANS- ANTIGEN BY POLY. AMIDOLYTIC 
GENE BY 12A8- CLONAL ACTIVITY 
MOUSE COPY MABELISA ELISA IN WHEY 
NUMBER NUMBER (mg/ml) (mg/ml) (%.N-PLASMA) 
5.4 14 0.05 + -0.01 0.14 + -0.01 N.D. 
6.4 1O 1.00 + -0.03 2.94 + -0.09 56.2 
4.2.10 1O 1.69 - -0.09 3.98 - -0.09 54.8 
5.2.12 2O 0.96+ -0.09 2.50 + -0.10 54.9 
7.2.2 2 0.33 + -0.03 0.89 + -0.14 N.D. 
7.5.4 3O O.96 - -0.04 1.99 - -0.33 18.8 
Finally, Some of the transgenic mice were Sacrificed and 
examined to determine the tissue specificity of expression of 
human protein C. RNAblots and immuno in situ histological 
examination showed that at least 99% of the protein C 
expression occurred in the mammary glands in these ani 
mals. These results contrast with the results achieved using 
whey acidic protein promoter constructs that contained only 
the 2.4 kb promoter fragment. Constructs using this pro 
moter to drive protein expression in transgenic mice engen 
dered expression that differed from the normal pattern of 
whey acidic protein expression during development and in 
adult tissues. In fact, this was true for the whey acidic 
protein itself. Thus, in addition to providing high levels of 
expression of a protein, the 4.2 kb 5’ WAP promoter frag 
ment also provides greater tissue specificity of expression in 
the adult mouse. 
(D) Purification of Protein C from Transgenic Mouse 
Whey 
Human protein C was partially purified from transgenic 
mouse whey by immunoaffinity chromatography using the 
12A8 monoclonal antibody immobilized on a Sepharose 
support. Bound protein C was eluted in 0.1M glycine, 0.02M 
histidine, 0.15M NaCl pH 10. Transgenic protein C purified 
in this manner revealed essentially the same banding pattern 
upon SDS-AAGE as a standard preparation of purified 
human protein C. 
SEQUENCE LISTING 
( 1) GENERAL INFORMATION: 
( i i i ) NUMBER OF SEQUENCES: 1 
( 2) INFORMATION FOR SEQ ID NO:1: 
( i) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH: 69 base pairs 
(B) TYPE: nucleic acid 
( C ) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
( x i ) SEQUENCE DESCRIPTION: SEQ ID NO:1: 
G G T AC GT C G A CA CAG G T G C C A G T G C C T C C A GAA T G T G G CA G CT CACA A G C C T C C T G CT GT 
T C G T G GC CA 
6 O 
69 
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What we claim is: 
1. A transgenic non-human mammal containing a DNA 
Sequence Stably integrated in its genome, wherein Said 
exogenous DNA sequence comprises the 5' 4.2 kb Sau3A 
Kpn1 promoter of the mouse whey acidic protein gene, 
operably linked to a DNA sequence encoding heterologous 
protein C and a Signal peptide, wherein Said whey acidic 
protein promoter is specifically active in mammary cells and 
Said Signal peptide is effective in directing the Secretion of 
Said protein C into the milk of Said transgenic mammal, 
wherein the activated form of Said Secreted protein C has an 
enzymatic activity of at least 50% as plasma-derived protein 
C, and wherein Said transgenic mammal is Selected from the 
group consisting of mice, rats, rabbits, pigs, sheep,goats and 
COWS. 
2. The transgenic non-human mammal of claim 1, 
wherein Said protein C is human protein C, and wherein Said 
DNA sequence encoding protein C further comprises regu 
latory elements located in the non-coding regions of the 
human protein C gene, wherein Said regulatory elements are 
the AUG start codon, donor and acceptor Splice Signals, the 
Secretion peptide, translation termination Signal, transcrip 
tion termination signal, and polvadenylation signal. 
3. The transgenic non-human mammal of claim 1, 
wherein Said DNA sequence encoding human protein C 
comprises the human protein C gene from 21 basepairs 
upstream of the protein C start condon to the NehI site in the 
3' end of the protein C gene. 
4. The transgenic non-human mammal of claim 1, 
wherein Said exogenous DNA sequence comprises a DNA 
Sequence comprising the 5' 4.2 kb Sau3A-Kpn1 promoter 
fragment of the mouse whey acidic protein promoter ligated 
directly or by a linker to a fragment of the human protein C 
gene beginning 21 basepairs upstream of the protein C Start 
codon and ending at the Nhe site in the 3' end of the protein 
C gene. 
5. A process for the production of heterologous protein C, 
comprising the Steps of: 
(A) providing a non-human transgenic mammal whose 
genome comprises a stably integrated DNA sequence 
comprising the 5' 4.2 kb Sau3A-Kpn1 promoter of the 
mouse whey acidic protein gene, operably linked to a 
DNA sequence encoding a heterologous protein C and 
a signal peptide, Said promoter being Specifically active 
in mammary cells and Said Signal peptide being effec 
tive in directing the Secretion of Said protein C into the 
milk of Said transgenic mammal, and wherein Said 
transgenic mammal is Selected from the group consist 
ing of mice, rats, rabbits, pigs, sheep, goats and cows; 
(B) producing milk from Said transgenic mammal, 
wherein Said milk contains Said Secreted protein C, and 
wherein the activated form of Said protein C has an 
enzymatic activity of at least 50% as plasma-derived 
protein C, 
(C) collecting said milk, and 
(D) isolating said protein C from Said milk. 
6. The process of claim 5, wherein said protein C is 
human protein C, and wherein Said DNA sequence encoding 
protein C further comprises regulatory elements located in 
the non-coding regions of the human protein C gene, 
wherein Said regulatory elements are the AUG Start codon, 
donor and acceptor Splice Signals, the Secretion peptide, 
translation termination Signal, transcription termination 
Signal, and polyadenylation signal. 
7. The process of claim 5, wherein said DNA sequence 
encoding human protein C comprises the human protein C 
gene from 21 basepairs upstream of the protein C Start codon 
to the Nhe site in the 3' end of the protein C gene. 
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8. The process of claim 5, wherein said DNA comprises 
a DNA sequence comprising the 5' 4.2 kb Sau3A-Kpn1 
promoter fragment of the mouse whey acidic protein pro 
moter ligated directly or by a linker to a fragment of the 
human protein C gene beginning 21 basepairs upstream of 
the protein C start codon and ending at the Nhe site in the 
3' end of the protein C gene. 
9. A process for producing non-human transgenic 
mammals, comprising the steps of (A) providing a mixture 
containing a double-stranded DNA; (B) Subjecting said 
mixture to anion-exchange high performance liquid chro 
matography to obtain purified double-stranded DNA; and 
thereafter (C) microinjecting an aqueous buffer Solution 
containing Said purified double-Stranded DNA into an ani 
mal embryo, wherein said double-stranded DNA is selected 
from the group consisting of a double-Stranded DNA com 
prising the 5' 4.2 kb Sau3A-Kpn1 promoter fragment of the 
mouse whey acidic protein promoter, a double-Stranded 
DNA comprising a fragment of the human protein C gene 
beginning 21 basepairs upstream of the protein C Start codon 
and ending at the Nhe site in the 3' end of the protein C 
gene, and a double-Stranded DNA comprising a DNA 
Sequence comprising the 5' 4.2 kb Sau3A-Kpn1 promoter 
fragment of the mouse whey acidic protein promoter ligated 
directly or by a linker to a fragment of the human protein C 
gene beginning 21 basepairs upstream of the protein C Start 
codon and ending at the Nhe site in the 3' end of the protein 
C gene, wherein the activated form of protein C encoded by 
said double-stranded DNA has an enzymatic activity of at 
least 50% as plasma-derived protein C, and wherein said 
transgenic mammal is Selected from the group consisting of 
mice, rats, rabbits, pigs, sheep, goats and cows. 
10. A transgenic non-human mammal containing a DNA 
Sequence Stably integrated in its genome, wherein Said DNA 
Sequence comprises the 5' 4.2 kb Sau3A-Kpn1 promoter 
fragment of the mouse whey acidic protein promoter, oper 
ably linked to a DNA sequence encoding a heterologous 
polypeptide whereby Said polypeptide is expressed Specifi 
cally in mammary cells of Said transgenic mammal and Said 
polypeptide comprises a signal peptide, Said Signal peptide 
being effective in directing the Secretion of Said polypeptide 
into the milk of Said mammal. 
11. The transgenic non-human mammal of claim 10, 
wherein Said transgenic non-human mammal is Selected 
from the group consisting of mice, rats, rabbits, pigs, sheep, 
goats and cows. 
12. The mammal of claim 11, wherein Said transgenic 
non-human mammal is sheep. 
13. The mammal of claim 11, wherein said transgenic 
non-human mammal is a goat. 
14. The mammal of claim 11, wherein Said transgenic 
non-human mammal is a cow. 
15. A process for the production of a heterologous 
polypeptide in the milk of a transgenic non-human mammal, 
comprising the Steps of: 
(A) providing a non-human transgenic mammal whose 
genome comprises a stably integrated DNA sequence 
comprising the 5' 4.2 kb Sau3A-Kpn1 promoter of the 
mouse whey acidic protein gene, operably linked to a 
DNA sequence encoding a heterologous polypeptide 
and a signal peptide, Said promoter being Specifically 
active in mammary cells and Said Signal peptide being 
effective in directing the Secretion of Said polypeptide 
into the milk of Said transgenic mammal; 
(B) producing milk from said transgenic mammal, 
wherein Said milk contains Said polypeptide; 
(C) collecting said milk, and 
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(D) isolating said polypeptide from Said milk. 
16. The process of claim 15, wherein said transgenic 
non-human mammal is Selected from the group consisting of 
mice, rats, rabbits, pigs, sheep,goats and cows. 
17. The process of claim 16, wherein said transgenic 5 
non-human mammal is a sheep. 
18. The process of claim 16, wherein said transgenic 
non-human mammal is a goat. 
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19. The process of claim 16, wherein said transgenic 
non-human mammal is a cow. 
20. An isolated DNA molecule which regulates the 
expression of a heterologous gene, wherein Said DNA mol 
ecule consists of the 5' 4.2 kb Sau3A-Kpn1 promoter of the 
mouse whey acidic protein gene. 
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